U.S. Surgical moving into cardiovascular/vascular, urology, orthopedic markets.
This article was originally published in The Gray Sheet
U.S. SURGICAL'S PRODUCT EXPANSION EFFORT WILL FOCUS ON CARDIOVASCULAR, vascular, urologic and orthopedic products, USSC Chairman, President and CEO Leon Hirsch told analysts at a May 16 session of the Alex. Brown health care seminar in Baltimore. "We are looking at a series of unique cardiovascular, urologic and orthopedic products -- some by acquisition, some through development work in our research department."
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.